Nymox Pharmaceutical Corp
NYMXF OTC
SEC CIK 1018735
Follow Nymox Pharmaceutical
Weekly email: filings, results
Net income
−$857K
+83.9% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$717K
+20.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY24 | - | −$4.5M |
| FY23 | $0 | −$8.8M |
| FY22 | $0 | −$6.6M |
| FY21 | $0 | −$12.5M |
| FY20 | $5K | −$11.7M |
| FY19 | $116K | −$13.2M |
| FY18 | $299K | −$10.6M |
| FY17 | $224K | −$13.4M |
| FY16 | $284K | −$13.1M |
| FY15 | $2.8M | −$17.9M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | 20% | −234400% | −234760% |
| FY19 | 50% | −11487.1% | −11346.6% |
| FY18 | 53.8% | −3558.9% | −3543.1% |
| FY17 | 33.5% | −5908.5% | −5995.1% |
| FY16 | 39.1% | −4531.3% | −4616.2% |
| FY15 | 94.2% | −639.6% | −648.1% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY24 | −$2.6M |
| FY23 | −$4.1M |
| FY22 | −$5.2M |
| FY21 | −$9.8M |
| FY20 | −$10.1M |
| FY19 | −$7.4M |
| FY18 | −$7.8M |
| FY17 | - |
| FY16 | −$4.5M |
| FY15 | - |
| FY14 | - |
- Nymox Pharmaceutical
- Healthcare median
Show the numbers
| Year | Nymox Pharmaceutical | Healthcare median |
|---|---|---|
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −234760% | −62.2% |
| FY19 | −11346.6% | −46.3% |
| FY18 | −3543.1% | −49.6% |
| FY17 | −5995.1% | −45.9% |
| FY16 | −4616.2% | −36% |
| FY15 | −648.1% | −38.4% |
| FY14 | - | −35.5% |